Key statistics
On Friday, Traws Pharma Inc (TRAW:NAQ) closed at 1.96, 102.06% above the 52 week low of 0.97 set on May 15, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.79 |
|---|---|
| High | 2.01 |
| Low | 1.79 |
| Bid | 1.92 |
| Offer | 2.00 |
| Previous close | 1.72 |
| Average volume | 217.60k |
|---|---|
| Shares outstanding | 7.99m |
| Free float | 6.40m |
| P/E (TTM) | 0.0609 |
| Market cap | 13.74m USD |
| EPS (TTM) | 28.24 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
More ▼
- Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
- Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
- Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
- Traws Pharma Reports Third Quarter 2025 Results and Business Highlights
- Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
- Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
- Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
- Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
- Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
- Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
More ▼
